Carcinoma, Hepatocellular: all 3,251 studies

Page 15 of 33. Open to participants first (976), then studies with results posted, then the rest; newest registration first within each.

• Implication of Long Non-coding RNA HOTTIP Haplotype on Liver Cancer MetastasisCompletedNCT06544005
• Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular CarcinomaActive, not recruitingNCT06524466Phase 2
• A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingNCT06521567Phase 1/2
• Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCCActive, not recruitingNCT06519721Not applicable
• Long-term Management of Patients With Ruptured HCCCompletedNCT06505291
• A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250
• Robotic Versus Laparoscopic Liver Resection for Hepatocellular CarcinomaCompletedNCT06496113
• A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Phase 1
• Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective StudyCompletedNCT06437457
• Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCCCompletedNCT06435013
• The Dual Impact of Cirrhosis on Transplantation for Hepatocellular Carcinoma：a Two-center Retrospective Cohort Study in ChinaCompletedNCT06420791
• Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)CompletedNCT06416683
• Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver TransplantationCompletedNCT06409507
• Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular CarcinomaSuspendedNCT06405061Phase 2
• Impact of Hepatectomy on HCC RecurrenceCompletedNCT06390228
• Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B PopulationActive, not recruitingNCT06379334
• Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular CarcinomaCompletedNCT06368349
• Screening for Chronic Liver Diseases in General PopulationActive, not recruitingNCT06366425Not applicable
• Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National DatabasesCompletedNCT06364839
• Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Phase 2
• EchoTip AcuCore Post-Market Clinical StudyCompletedNCT06358001
• Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1CompletedNCT06354387Phase 1
• A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid CancersCompletedNCT06345001Phase 1
• Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)WithdrawnNCT06337162Phase 1
• The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral DrugsActive, not recruitingNCT06325826
• Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in ChinaCompletedNCT06315101
• Pharmacogenetic of Doxorubicin in HCC.CompletedNCT06313047
• Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High RiskActive, not recruitingNCT06312826Not applicable
• Development of a Neuronal MicroscopeCompletedNCT06311396Not applicable
• Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular CarcinomaTerminatedNCT06302400Not applicable
• Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic ModellingCompletedNCT06298123
• Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCCCompletedNCT06294808
• The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After HepatectomyActive, not recruitingNCT06278701Not applicable
• Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTTCompletedNCT06265883
• Survival Analysis: TACE vs. Combination Therapy in HCCCompletedNCT06261138
• Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver CancerCompletedNCT06261047
• Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave AblationCompletedNCT06248554Not applicable
• Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.Active, not recruitingNCT06248528Not applicable
• Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal HypertensionCompletedNCT06245798
• Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver FunctionCompletedNCT06245785
• A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsActive, not recruitingNCT06239155Phase 1/2
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor ThrombosisCompletedNCT06233981Phase 2
• Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver TransplantCompletedNCT06233708
• TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular CarcinomaCompletedNCT06232759Phase 2
• Brazilian Reality of Hepatocellular CarcinomaCompletedNCT06230328
• A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)Active, not recruitingNCT06218511Phase 1
• Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 TreatmentWithdrawnNCT06217094Phase 1
• BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid TumorsActive, not recruitingNCT06205706Phase 1/2
• Lipiodol Deposition Using Endhole vs. Pressure-Modulated DeliveryActive, not recruitingNCT06204159Not applicable
• Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular CarcinomaCompletedNCT06199297
• Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical TrialActive, not recruitingNCT06193733Phase 2
• CT Imaging for Guiding PA-TACE for HCCCompletedNCT06156748
• Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular CarcinomaActive, not recruitingNCT06138769Phase 2
• Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular CarcinomaCompletedNCT06114251
• TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular CarcinomaCompletedNCT06114082Phase 2
• A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingNCT06109272Phase 2/3
• ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma RuptureCompletedNCT06102278
• The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational StudyActive, not recruitingNCT06096896
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisActive, not recruitingNCT06096779Phase 2
• A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT06092112Early Phase 1
• Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular CarcinomaCompletedNCT06086002Not applicable
• A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaActive, not recruitingNCT06084884Phase 1/2
• Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular CarcinomaStatus unknownNCT06061445Not applicable
• Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation ProcedureActive, not recruitingNCT06045975Phase 2
• The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACECompletedNCT06041425Phase 4
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
• Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRICompletedNCT06037343
• Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.CompletedNCT06030895Not applicable
• Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver TransplantationActive, not recruitingNCT06018857
• Surgical Resection for Hepatocellular CarcinomaCompletedNCT06013657
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnNCT06006286Phase 1/2
• Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk ScoringCompletedNCT06005883
• A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced CancerActive, not recruitingNCT06005740Phase 1
• Multi-center Clinical Study on the Decision Tree of Precision Hepatectomy in China Precision Hepatectomy Decision TreeStatus unknownNCT05986383
• Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCCCompletedNCT05971108Phase 4
• Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05953337Not applicable
• An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCCCompletedNCT05932836
• Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular CarcinomaActive, not recruitingNCT05925413Phase 2
• Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft RejectionStatus unknownNCT05913583
• Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular CarcinomaCompletedNCT05907772
• A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Phase 3
• Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05901194Phase 1/2
• Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular CarcinomaActive, not recruitingNCT05889949
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TWithdrawnNCT05886257Phase 2
• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
• PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Phase 2
• The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular CarcinomaStatus unknownNCT05862181
• Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
• Paraneoplastic Syndrome in Hepatocellular Carcinoma PatientsStatus unknownNCT05846035
• Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular CarcinomaTerminatedNCT05845502Not applicable
• Prognostic Models for HCC Based on Tumor MicronecrosisStatus unknownNCT05837065
• Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection RecurrenceCompletedNCT05823584
• Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05822752Phase 2
• Prognostic Role of HVPG and ICG-R15 in the Short- and Medium-term Results of the Surgery of HCC on CirrhosisStatus unknownNCT05800561
• Microwave Ablation Versus Laparoscopic Hepatectomy for 3-5cm Hepatocellular CarcinomaCompletedNCT05796700Not applicable
• AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic DiseaseSuspendedNCT05791448Phase 1
• Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
• Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)TerminatedNCT05770882Phase 1/2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TStatus unknownNCT05760599Phase 2
• The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular CarcinomaStatus unknownNCT05760430Phase 2

← Carcinoma, Hepatocellular overview